ASSET PURCHASE AGREEMENT WITH TRIGEMINA (Details Narrative) - USD ($) |
3 Months Ended | 9 Months Ended | ||||
---|---|---|---|---|---|---|
Jun. 11, 2020 |
Sep. 30, 2020 |
Sep. 30, 2019 |
Sep. 30, 2020 |
Sep. 30, 2019 |
Dec. 31, 2019 |
|
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 | $ 0.001 | |||
Research and development | $ 8,813,000 | $ 5,052,000 | $ 24,060,000 | $ 12,502,000 | ||
Asset Purchase Agreement [Member] | Trigemina, Inc.[Member] | ||||||
Payment for purchase of assets | $ 824,759 | |||||
Number of shares issued (in shares) | 2,000,000 | |||||
Common stock, par value (in dollars per share) | $ 0.001 | |||||
Common stock value (per share) | $ 0.68 | |||||
Research and development | $ 2,400,000 | |||||
Assignment and Assumption Agreement [Member] | Leland Stanford Junior University [Member] | ||||||
Payment for purchase of assets | $ 250,241 |
X | ||||||||||
- Definition Common stock value per share. No definition available.
|
X | ||||||||||
- Definition Face amount or stated value per share of common stock. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Number of new stock issued during the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|